• Review • Previous Articles     Next Articles

Antiviral therapy in patients with hepatitis B virus-related liver cirrhosis

GU Lei-lei1, ZHANG Xin-xin2   

  1. 1.Department of Gastroenterology, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 201801, China; 2.Department of Infectious Diseases, Ruijin Hospital, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Online:2015-11-28 Published:2016-01-13
  • Supported by:

    National Natural Science Foundation of China， 81371860

PDF (PC)

1137

Abstract:

Chronic hepatitis B virus (HBV) infection is one of the major causes of liver cirrhosis. The progression of cirrhosis is associated with the HBV DNA level. The antiviral therapy can inhibit the viral replication, reduce complications of cirrhosis, and improve the survival rate of patients with cirrhosis. It is important to provide effective antiviral therapy for the treatment of HBV-related liver cirrhosis. Currently, antiviral drugs include nucleos(t)ide analogues (Nucs) and IFNα. This paper briefly introduces the application of these antiviral drugs to patients with cirrhosis and particularly highlights the recommendations in native and foreign practice guidelines for the treatment of HBV-related liver cirrhosis.

Key words: cirrhosis, chronic hepatitis B, antiviral therapy, nucleos(t)ide analogues, interferon